(2R,3R,4R)-4-benzyloxy-N-benzyloxycarbonyl-2-benzyloxymethyl-pyrrolidin-3-yl 2,3,6-tri-O-benzyl-4-O-{(4-O-β-D-glucopyranosyl)-β-D-glucopyranosyl}-α-D-galactopyranoside | 736969-96-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2R,3R,4R)-4-benzyloxy-N-benzyloxycarbonyl-2-benzyloxymethyl-pyrrolidin-3-yl 2,3,6-tri-O-benzyl-4-O-{(4-O-β-D-glucopyranosyl)-β-D-glucopyranosyl}-α-D-galactopyranoside
• 英文别名: (2R,3R,4R)-4-Benzyloxy-N-benzyloxycarbonyl-2-benzyloxymethyl-pyrrolidin-3-yl 2,3,6-tri-O-benzyl-4-O-{4-O-(beta-D-glucopyranosyl)-beta-D-glucopyranosyl}-alpha-D-galactopyranoside；benzyl (2R,3R,4R)-3-[(2S,3R,4S,5S,6R)-5-[(2S,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-bis(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-yl]oxy-4-phenylmethoxy-2-(phenylmethoxymethyl)pyrrolidine-1-carboxylate
• CAS: 736969-96-3
• 化学式: C₆₆H₇₇NO₂₀
• 分子量: 1204.33
• InChiKey: RUCUNOPJXUROJE-YYPVQEMLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  87
• 可旋转键数：
  28
• 环数：
  10.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  273
• 氢给体数：
  7
• 氢受体数：
  20

反应信息

• 作为反应物：
  描述：

  (2R,3R,4R)-4-benzyloxy-N-benzyloxycarbonyl-2-benzyloxymethyl-pyrrolidin-3-yl 2,3,6-tri-O-benzyl-4-O-{(4-O-β-D-glucopyranosyl)-β-D-glucopyranosyl}-α-D-galactopyranoside 在 palladium dihydroxide 盐酸 、 氢气 作用下， 以 甲醇 为溶剂， 反应 4.0h， 以32%的产率得到(2R,3R,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidin-3-yl 4-0-{4-O-(β-D-glucopyranosyl)-β-D-glucopyranosyl}-α-D-galactopyranoside
  参考文献：
  名称：

  EP1792620

  摘要：

  公开号：
• 作为产物：
  描述：

  (2R,3R,4R)-4-benzyloxy-N-benzyloxycarbonyl-2-benzyloxymethylpyrrolidin-3-yl 2,3,6-tri-O-benzyl-4-O-{2,3,6-tri-O-benzyl-4-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-β-D-glucopyranosyl}-α-D-galactopyranoside 在 甲醇 、 potassium carbonate 作用下， 反应 6.0h， 以61%的产率得到(2R,3R,4R)-4-benzyloxy-N-benzyloxycarbonyl-2-benzyloxymethyl-pyrrolidin-3-yl 2,3,6-tri-O-benzyl-4-O-{(4-O-β-D-glucopyranosyl)-β-D-glucopyranosyl}-α-D-galactopyranoside
  参考文献：
  名称：

  EP1792620

  摘要：

  公开号：

文献信息

• Oligosaccharide derivative
  申请人：Honda Takeshi

  公开号：US20060025350A1

  公开（公告）日：2006-02-02

  Compounds having the formula (I): wherein A represents a group such as a cyclic group, R 1 and R 2 represent groups such as alkyl groups or hydroxymethyl groups, and n represents 1 or 2, or pharmacologically acceptable salts thereof or pharmacologically acceptable esters thereof have superior activity and stability, and are useful for the treatment and/or prevention of diabetes mellitus, or the like.

  具有化学式（I）的化合物：其中A代表环状基团，R1和R2代表烷基或羟甲基等基团，n代表1或2，或其药学上可接受的盐或酯具有卓越的活性和稳定性，并且可用于治疗和/或预防糖尿病等疾病。
• Oligosaccharide Derivative
  申请人：Honda Takeshi

  公开号：US20080194495A1

  公开（公告）日：2008-08-14

  Compounds having the formula (I): wherein A represents a group such as a cyclic group, R 1 and R 2 represent groups such as alkyl groups or hydroxymethyl groups, and n represents 1 or 2, or pharmacologically acceptable salts thereof or pharmacologically acceptable esters thereof have superior activity and stability, and are useful for the treatment and/or prevention of diabetes mellitus, or the like.

  具有式(I)的化合物：其中A表示环状基团，R1和R2表示烷基或羟甲基等基团，n表示1或2，或其药学上可接受的盐或酯，在活性和稳定性方面具有优越性，可用于治疗和/或预防糖尿病等疾病。
• MEDICINAL COMPOSITION CONTAINING DIABETES REMEDY
  申请人：Sankyo Company, Limited

  公开号：EP1792620A1

  公开（公告）日：2007-06-06

  A pharmaceutical composition effective for the prophylaxis and treatment of, diabetes is provided. This pharmaceutical composition comprises the combination of an α-amylase inhibitor selected from a compound represented by the following general formula (I): [wherein A represents, for example, a cyclic group, etc. R1 and R2 represent an alkyl group, hydroxymethyl group, etc., and n represents 1 or 2], or a pharmacologically acceptable salt or ester thereof, and at least one type of drug selected from an insulin sensitizer, an insulin secretagogue, a biguanide drug, an insulin preparation and a DPP-IV inhibitor.

  本发明提供了一种有效预防和治疗糖尿病的药物组合物。这种药物组合物包括一种α-淀粉酶抑制剂，该抑制剂选自以下通式（I）所代表的化合物： [其中 A 代表环状基团等。 R1和R2代表烷基、羟甲基等，n代表1或2]，或其药理上可接受的盐或酯，以及至少一种选自胰岛素增敏剂、胰岛素促泌剂、双胍类药物、胰岛素制剂和DPP-IV抑制剂的药物。
• OLIGOSACCHARIDE DERIVATIVE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1589023B1

  公开（公告）日：2010-08-25
• US7361744B2
  申请人：——

  公开号：US7361744B2

  公开（公告）日：2008-04-22